Teleflex Q3 2026 Earnings: Adjusted EPS Rises on Nearly Flat Revenue

Teleflex (NYSE: TFX) reported Q3 2026 continuing-operations revenue of $567.8 million, up 0.2% year over year, and adjusted diluted EPS of $2.63, up from $1.89. GAAP diluted EPS improved to $1.30 from a loss of $1.32, as margin expansion and tariff refunds helped earnings grow faster than reported revenue.

Core Earnings Data

Reported revenue was nearly flat, but pro forma adjusted constant-currency revenue grew 3.0%. This measure adjusts for the Vascular Intervention acquisition, products discontinued at the end of 2025, the Italian payback measure, and foreign exchange.

Adjusted diluted EPS increased by approximately 39%, while GAAP EPS returned to positive territory. All figures below are from continuing operations, which exclude the Acute Care, Interventional Urology, and OEM businesses classified as discontinued operations.

Business and Segment Performance

Teleflex changed its segment reporting during the quarter from a geographic structure to three global product-based units: Vascular, Interventional, and Surgical. Prior-period figures were restated to match the new presentation.

Vascular and Surgical generated the strongest growth. Interventional declined on a reported basis but returned to slight growth after applying the company’s pro forma and constant-currency adjustments.

Combined segment revenue increased 1.8%, faster than the 0.2% increase in consolidated revenue. The difference reflects $9.0 million of prior-year “Other” revenue associated with reductions in reserves for the Italian payback measure, with no comparable amount in Q3 2026.

Tariff Refunds Helped Earnings Outpace Revenue

Teleflex received $39.2 million of refunds following the invalidation of tariffs imposed under the International Emergency Economic Powers Act. That total included amounts associated with businesses classified as discontinued operations.

Continuing operations recognized a $25.3 million benefit that reduced cost of sales. Of this amount, $16.5 million related to tariffs recognized in 2026 and was included in the company’s non-GAAP results. Another $8.8 million related to tariffs recognized in 2025 and was excluded from adjusted results because Teleflex did not consider it a normal recurring operating item.

The treatment is important when assessing the EPS increase: adjusted earnings still benefited from the $16.5 million current-year refund, although management said earnings growth remained robust even when excluding the refunds. Teleflex did not provide a separate EPS figure excluding the benefit.

Strategic Divestitures and Capital Allocation

Teleflex completed the sale of its OEM business on August 3, 2026, for $1.5 billion in cash and received $1.25 billion in after-tax proceeds. It subsequently repaid its $700 million Term Loan A-2 and reduced borrowings under its revolving credit facility.

The pending sale of the Acute Care and Interventional Urology businesses remains subject to regulatory approval and other closing conditions. Teleflex is working toward completion by the end of 2026, but acknowledged that closing could extend into 2027.

From July 1 through the earnings release date, Teleflex repurchased $350 million of common stock through a $250 million accelerated share repurchase and $100 million of open-market purchases. The company acquired 2.7 million shares at an average price of $128.96 and had $400 million remaining under its authorization as of November 5, 2026.

Cash, cash equivalents, and restricted cash equivalents totaled $444.3 million at September 30, up from $402.7 million at the end of 2025. Over the same period, inventories declined to $384.4 million from $404.4 million, while net accounts receivable increased to $379.6 million from $345.6 million.

2026 Guidance

Teleflex maintained its underlying revenue growth outlook but reduced its GAAP revenue growth range because the expected positive foreign-exchange contribution fell to approximately 0.5% from 0.7%. The company raised both GAAP and adjusted EPS guidance and increased its adjusted operating margin assumption by approximately one percentage point.

The margin assumption includes the $16.5 million of 2026 tariff refunds recognized in the third quarter. EPS guidance also reflects the completed debt repayment and $600 million of 2026 share repurchases, but excludes potential additional repurchases, further debt reduction using divestiture proceeds, and benefits from transition or manufacturing services agreements that would begin after the pending divestiture closes.

Risks Investors Need to Watch

• Underlying growth remains moderate: Pro forma adjusted constant-currency revenue increased 3.0%, while Interventional grew only 0.2% on that basis. The segment’s integration and growth trajectory remain important to the consolidated outlook.
• Tariff refunds affect comparability: The refunds supported third-quarter profitability and the full-year margin assumption, making comparisons between reported earnings growth and recurring operating performance less straightforward.
• Divestiture timing is not certain: Regulatory review could push the Acute Care and Interventional Urology sale into 2027, delaying completion of Teleflex’s planned business simplification.
• Foreign exchange is affecting reported guidance: A smaller expected currency benefit led Teleflex to reduce its GAAP revenue growth outlook even though its constant-currency range was unchanged.
• Transformation execution remains central: Teleflex is simultaneously integrating Vascular Intervention, reorganizing around three global business units, and completing strategic divestitures.

Summary

Teleflex’s Q3 2026 results combined nearly flat reported revenue with substantially higher adjusted EPS. Vascular and Surgical drove underlying growth, Interventional returned to modest growth on an adjusted constant-currency basis, and tariff refunds supported profitability. The main issues to monitor are Interventional’s progress, completion of the remaining divestiture, and whether Teleflex can deliver its maintained revenue growth range and higher margin assumption.